Scotts Miracle-Gro Reports Strong Q2 Continuing Operations, Details Hawthorne Divestiture & Litigation Update
Summary
Scotts Miracle-Gro reported strong Q2 results for its continuing operations, marked by increased sales and improved gross margin, alongside detailed updates on the Hawthorne divestiture and ongoing legal proceedings.
Key Events
-
Strong Q2 Performance in Continuing Operations
Net sales from continuing operations increased by 5.0% to $1,459.5 million for the three months ended March 28, 2026, compared to $1,389.7 million in the prior year. Gross margin rate improved significantly to 41.8% from 39.0% year-over-year, driven by favorable mix, higher Roundup commissions, and lower manufacturing costs. Diluted EPS from continuing operations rose to $4.46 from $3.78.
-
Hawthorne Divestiture Details and Impact
The company completed the sale of its Hawthorne business in North America on April 8, 2026, receiving 213.0 million common shares of Vireo Growth Inc. (representing approximately 14% of Vireo's outstanding shares) and a warrant to acquire an additional 80.0 million shares at a strike price of $0.85 per share. This strategic divestiture resulted in a pre-tax valuation adjustment charge of $134.4 million for the six months ended March 28, 2026, contributing to a $102.0 million loss from discontinued operations, net of tax.
-
Improved Cash Flow and Debt Management
Net cash used in operating activities improved to $150.4 million for the six months ended March 28, 2026, compared to $257.2 million in the prior year, reflecting higher sales and optimized inventory production. Total debt decreased to $2,360.8 million from $2,563.1 million year-over-year, and the company's leverage ratio improved to 3.71, well within the maximum permitted ratio of 5.00.
-
Update on Securities Litigation
The U.S. District Court partially granted and partially denied the defendants' motion to dismiss in the consolidated securities litigation on April 22, 2026, indicating that the lawsuits alleging misstatements about inventories, sales, and business prospects will proceed.
Analysis
This quarterly report provides a comprehensive view of Scotts Miracle-Gro's financial health, highlighting robust performance in its continuing operations with increased sales and improved profitability. The detailed disclosure of the Hawthorne divestiture, including the consideration received and the significant valuation charge, offers crucial insight into the company's strategic shift. Additionally, the update on ongoing securities litigation is an important development for investors to monitor, as the partial denial of the motion to dismiss indicates the lawsuits will proceed. Overall, the filing reinforces the strength of the core business while providing transparency on strategic changes and legal risks.
At the time of this filing, SMG was trading at $62.85 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $52.00 to $72.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.